English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduCHICAGO, June 2, 2021 /PRNewswire/ — On, or before, Monday, June 7, the FDA is expected to make a decision on aducanumab (Biogen), a new type of Alzheimer’s treatment. If approved, the decision would be historic. Aducanumab would be the first drug to slow Alzheimer’s disease, marking the beginning of a completely new future for Alzheimer’s treatments.
The Alzheimer’s Association urgently supports FDA approval of the treatment based on clinical trial results that showed a 22% reduction in cognitive and functional decline — something that could make a meaningful difference in the lives of individuals living with Alzheimer’s and their families. With more than 6 million Americans living with Alzheimer’s, the need for a treatment for a disease that has no survivors has never been greater.
Interviews are available ahead of, or immediately following, decision with the following:
- Alzheimer’s Association leadership: to discuss impact of the FDA’s decision on the Alzheimer’s community and future research.
- Individuals living with early onset Alzheimer’s and care partners: to discuss their personal experience with the therapy and hopes for the treatment.
- Science experts: to discuss the impact on research and the drug development pipeline.
- Neurologists, clinicians and health care experts: to discuss impact on care, treatment and the lives of people with early-onset Alzheimer’s and their care partners.
Please contact [email protected] to schedule an interview and for more information.
About the Alzheimer’s Association®
The Alzheimer’s Association leads the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementia®. For more information, visit www.alz.org or call the 24/7 Helpline at 800.272.3900.
